Dr. reddy's successfully completes full set of clinical studies of its rituximab biosimilar for filing in the u.s., europe

Hyderabad, india--( business wire )--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy; hereafter referred to as “dr. reddy's”), a global pharmaceutical company, announced that it has successfully completed the full set of clinical studies of its proposed rituximab biosimilar candidate, drl_ri, for filing in highly regulated markets such as the united states, europe and other regions.
RDY Ratings Summary
RDY Quant Ranking